CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Los Angeles |
Dr. Caroline Y. Kuo |
Therapeutic Translational Research Projects |
Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome |
$4,896,628 |
| Stanford University |
Dr. Theodore Leng |
Therapeutic Translational Research Projects |
NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
| Stanford University |
Dr. Bertha Chen |
Therapeutic Translational Research Projects |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
| Children’s Hospital of Los Angeles |
Dr. Mark R Frey |
Therapeutic Translational Research Projects |
ASCENT- Advanced Stem Cell Enteric Neuropathy Therapy |
$7,077,352 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Huinan Hannah Liu |
SPARK |
Summer Training and Research Inspiration for Diverse Pipeline Engagement toward Advancing Stem Cell Treatment (STRIDE) |
$507,560 |
| University of California, San Francisco |
Katherine Nielsen |
SPARK |
Stem Cell Summer Research Experiences |
$508,750 |
| Stanford University |
Paul J. Utz |
SPARK |
Stem Cell and Regenerative Medicine- High School Summer Research Internship |
$485,158 |
| University of California, Davis |
Dr. Fernando A Fierro PhD |
SPARK |
Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility |
$499,573 |
| Charles R. Drew University of Medicine and Science |
Dolores Caffey-Fleming |
SPARK |
Exposing Students to Regenerative Medicine (ExStRM) |
$482,730 |
| Children’s Hospital of Los Angeles |
Dr. Mark R Frey |
SPARK |
Stem Cell and Regenerative Medicine Summer Internships for High School Students from Under-Served Communities |
$508,750 |
| University of California, San Diego |
James Murphy |
SPARK |
Summer Program To Accelerate Regenerative Medicine Knowledge (SPARK) |
$488,621 |
| Sanford Burnham Prebys Medical Discovery Institute |
Sanjeev Ranade |
SPARK |
Stem Cells & STEM Education – a Summer Internship Program for California High School Students |
$509,000 |
| City of Hope, Beckman Research Institute |
Dr. David Kong Ann |
SPARK |
Train, Educate, and Accelerate Mastery of Stem cell research (TEAMS) program |
$499,408 |
| UCSF Benioff Children’s Hospital Oakland |
Ellen B Fung |
SPARK |
Supporting Underrepresented STudents Adapting to Change: Summer Program to Accelerate Regenerative Medicine Knowledge (SUSTAIN a SPARK) |
$254,964 |
| Cedars-Sinai Medical Center |
Cedars-Sinai Medical Center Wafa Tawackoli |
SPARK |
Mentored High School Summer Research Program |
$508,750 |
| Berkeley City College |
Dr. Barbara Des Rochers |
Bridges |
CIRM Bridges to Stem Cell Research and Therapy |
$3,224,918 |
| Cal State Fullerton |
Dr. Nilay V Patel |
Bridges |
Bridges to Stem Cell Research and Therapy: A Talent Development Program for Training Diverse Undergraduates for Careers in Regenerative Medicine |
$3,530,873 |
| City College Of San Francisco |
Dr. Carin Zimmerman |
Bridges |
Building Career Pathways into Stem Cell Research and Therapy Development |
$3,195,638 |
| Cal Poly Corporation, an Auxiliary of California Polytechnic State University, San Luis Obispo |
Trevor Cardinal |
Bridges |
Training Masters Students to Advance the Regenerative Medicine Field |
$3,931,800 |
| Cal State Univ, San Bernadino |
Dr. Nicole Bournias-Vardiabasis |
Bridges |
Stem Cell Scholars: a workforce development pipeline, educating, training and engaging students from basic research to clinical translation. |
$4,327,800 |
| The University Corporation at California State University, Northridge |
Dr. Cindy S Malone |
Bridges |
CSUN CIRM Bridges3.0 Stem Cell Research & Therapy Training Program |
$4,327,057 |
| California State University, Channel Islands |
Dr. Nitika S Parmar |
Bridges |
CIRM Graduate Student Training in Stem Cell Sciences in the Stem Cell Technology and Lab Management Emphasis of the MS Biotechnology Program |
$4,270,367 |
| San Francisco State University |
Dr. Lily Chen |
Bridges |
CIRM Bridges Science Master’s Program |
$4,049,650 |
| Cal State Univ, Sacramento |
Kimberly A Mulligan |
Bridges |
Strengthening the Pipeline of Master’s-level Scientific and Laboratory Personnel in Stem Cell Research |
$2,828,738 |
| SJSU Research Foundation |
Bree Grillo – Hill |
Bridges |
Stem Cell Internships in Laboratory-based Learning ( SCILL) continue to expand the scientific workforce for stem cells research and therapies . |
$4,327,800 |
| Cal State Univ, Long Beach |
Deborah Ann Fraser |
Bridges |
CIRM Regenerative Medicine and Stem Cell Research Biotechnology Training Program |
$3,901,802 |
| Humboldt State University Sponsored Programs Foundation |
Dr Amy Sprowles |
Bridges |
CIRM Bridges 3.0 |
$4,212,071 |
| San Diego State University Foundation |
Ralph Feuer |
Bridges |
Bridges to Stem Cell Research Internship Program |
$3,530,717 |
| California State University San Marcos Corporation |
Dr. Bianca Romina Mothé |
Bridges |
CIRM Bridges to Stem Cell Research and Therapy Training Grant |
$4,327,800 |
| Pasadena City College |
Dr. Pamela Eversole-Cire |
Bridges |
Bridges to Stem Cell Research and Therapy at Pasadena City College |
$3,254,471 |
| Stanford University |
Dr. Everett H. Meyer |
Conference II |
Cellular Immune Tolerance Symposium |
$50,000 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Clinical Trial Stage Projects |
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy |
$13,999,983 |
| Ray Therapeutics, INC |
Paul Bresge |
Clinical Trial Stage Projects |
Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa |
$7,975,224 |
| University of California, San Francisco |
Dr Morton Cowan |
Clinical Trial Stage Projects |
Gene Therapy for Artemis-Deficient Severe Combined Immunodeficiency Using a Self-Inactivating Lentiviral Vector |
$14,999,999 |
| Tenaya Therapeutics, Inc. |
Dr. Matthew Pollman |
Clinical Trial Stage Projects |
Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) |
$8,000,000 |
| Tr1X Inc. |
Maria Grazia Roncarolo |
Clinical Trial Stage Projects |
TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies |
$8,000,000 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Clinical Trial Stage Projects |
Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS-ADA lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$14,325,181 |
| Fate Therapeutics, Inc. |
Dr. Vaneet Sandhu |
Clinical Trial Stage Projects |
A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus |
$7,934,448 |
| Senti Biosciences, Inc. |
Rochelle Emery |
Clinical Trial Stage Projects |
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies |
$8,000,000 |
| Nexcella, Inc. |
Ilya Rachman MD PhD |
Clinical Trial Stage Projects |
Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis |
$7,999,467 |
| University of California, San Francisco |
Dr. Hideho Okada |
Clinical Trial Stage Projects |
Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma |
$10,927,618 |
| Aspen Neuroscience |
Dr. Edward Wirth III |
Clinical Trial Stage Projects |
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease |
$8,000,000 |
| Allogene Therapeutics |
Dr. John Le Gall |
Clinical Trial Stage Projects |
A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC) |
$9,238,404 |
| University of California, San Francisco |
Noriyuki Kasahara |
Clinical Trial Stage Projects |
A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma |
$11,807,220 |
| Luxa Biotechnology |
Dr. Jeffrey H Stern |
Clinical Trial Stage Projects |
RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration |
$4,009,675 |
| Rocket Pharmaceuticals, Inc. |
Dr. Jonathan Schwartz |
Clinical Trial Stage Projects |
A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease |
$5,808,735 |
| University of California, Davis |
Dr. Diana L. Farmer |
Clinical Trial Stage Projects |
The CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele |
$8,996,477 |
| Stanford University |
Dr. Reena Parada Thomas |
Clinical Trial Stage Projects |
Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme |
$11,999,991 |
| City of Hope, Beckman Research Institute |
Elizabeth Budde |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
$11,983,547 |
| University of California, San Diego |
Prof. Olivia Kim-McManus |
Clinical Trial Stage Projects |
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A |
$960,713 |
